Though ischemic outcomes numerically favored the Amulet, confirmation in future studies is needed, experts say.

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s Electrophysiology (EP) ...

Boston Scientific plans to break ground soon on a major expansion in Maple Grove, a project that’s up for $1.66 million in ...

A diversified portfolio, strategic acquisitions, and aggressive R&D have driven Boston Scientific's recent ... and structural heart (WATCHMAN) has recently set it apart. Its operating margin ...

Boston Scientific’s product portfolio is a key driver of its success, with several standout offerings contributing to its strong market position. The Farapulse and Watchman products have shown ...

Boston Scientific Corporation develops ... and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices ...

Boston Scientific Corporation BSX ... In Japan, strong contributions from AGENT DCB, Rezum, WATCHMAN FLEX Pro and a very early contribution from FARAPULSE drove growth. The company recognized ...